Bothell, Washington
United States
113
2026-02-05
63
2025-12-16
These are the the leading inventors for applications assigned to SEAGEN INC.:
SEAGEN INC. based in Bothell, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
#2 | 2026-01-01PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF
#3 | 2025-09-04ANTI-ALPP/ALPPL2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
#4 | 2025-08-07CAMPTOTHECIN CONJUGATES
#5 | 2025-06-05METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CD30 ANTIBODY DRUG CONJUGATE
#6 | 2025-05-01METHODS FOR TREATING NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
#7 | 2025-02-27METHODS FOR TREATING MUSCLE INVASIVE UROTHELIAL CANCER OR MUSCLE INVASIVE BLADDER CANCER WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
#8 | 2024-12-19WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES
#9 | 2024-11-14Improved Antibody Masking Domains
#10 | 2024-10-24Antibody Masking Domains
#11 | 2024-10-17Compositions and Methods for Targeting Cancer Stem Cells
#12 | 2024-10-17Compositions and Methods for Targeting Cancer Stem Cells
#13 | 2024-10-17Glycan-Interacting Compounds and Methods of Use
#14 | 2024-05-30GLYPICAN 3 ANTIBODIES AND CONJUGATES THEREOF
#15 | 2024-05-23METHODS OF TREATING CANCER WITH A COMBINATION OF A NONFUCOSYLATED ANTI-CD70 ANTIBODY AND A CD47 ANTAGONIST
#16 | 2024-04-25 ā Patent 12,496,353 granted on 2025-12-16SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY
#17 | 2024-04-11 ā Patent 12,257,281 granted on 2025-03-25Hydrophilic antibody-drug conjugates
#18 | 2024-04-04BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS
#19 | 2024-03-14VARIANT TARGET BINDING AGENTS AND USES THEREOF
#20 | 2024-03-07 ā Patent 12,268,751 granted on 2025-04-08Anti-Ī±VĪ²6 antibodies and antibody-drug conjugates
#21 | 2024-02-08ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS
#22 | 2024-01-25Methods of Treating Cancer with Anti-TIGIT Antibodies
#23 | 2024-01-11Glycan-Interacting Compounds and Methods of Use
#24 | 2024-01-04Compositions and Methods for Targeting Cancer Stem Cells
#25 | 2024-01-04Compositions and Methods for Targeting Cancer Stem Cells
#26 | 2024-01-04Glycan Analysis and Profiling
#27 | 2024-01-04Glycan-Interacting Compounds and Methods of Use
#28 | 2023-12-07 ā Patent 12,048,698 granted on 2024-07-30Treatment of HER2 positive cancers
#29 | 2023-11-16METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
#30 | 2023-11-02ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
#31 | 2023-10-19Glycan-Interacting Compounds and Methods of Use
#32 | 2023-10-19METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
#33 | 2023-10-05Compositions and Methods for Treating Cancer
#34 | 2023-08-31Combination Therapy
#35 | 2023-08-31MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC)
#36 | 2023-08-03ANTIBODIES TO INTEGRIN AVB6 AND USE OF SAME TO TREAT CANCER
#37 | 2023-07-13ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS
#38 | 2023-06-22METHODS OF TREATING CANCER USING A COMBINATION OF ANTI-CD30 ANTIBODY-DRUG CONJUGATES
#39 | 2023-05-11Glycan-Interacting Compounds and Methods of Use
#40 | 2023-05-04Anti-TIGIT Antibodies
#41 | 2023-03-23 ā Patent 12,036,286 granted on 2024-07-16Selective drug release from internalized conjugates of biologically active compounds
#42 | 2023-02-16Anti-TIGIT Antibodies
#43 | 2023-02-02 ā Patent 12,194,321 granted on 2025-01-14Camptothecin conjugates
#44 | 2023-02-02HIGH PERFORMANCE LIQUID CHROMATOGRAPHY QUANTIFICATION OF EXCIPIENTS
#45 | 2023-01-26Compositions and Methods for Targeting Cancer Stem Cells
#46 | 2023-01-26TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
#47 | 2023-01-26Compositions and Methods for Targeting Cancer Stem Cells
#48 | 2023-01-05Glycan-Interacting Compounds and Methods of Use
#49 | 2023-01-05TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
#50 | 2022-11-24 ā Patent 12,590,968 granted on 2026-03-31DETECTION AND TREATMENT OF CD30+ CANCERS
#51 | 2022-09-29Methods of Purifying Masked Antibodies
#52 | 2022-09-15 ā Patent 11,559,558 granted on 2023-01-24Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
#53 | 2022-08-18Glycan-Interacting Compounds and Methods of Use
#54 | 2022-07-28Masked Antibody Formulations
#55 | 2022-07-21 ā Patent 11,793,880 granted on 2023-10-24Conjugates of quaternized tubulysin compounds
#56 | 2022-06-09 ā Patent 12,257,340 granted on 2025-03-25Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
#57 | 2022-06-09 ā Patent 11,938,194 granted on 2024-03-26Cysteine mutated antibodies for conjugation
#58 | 2022-06-02 ā Patent 11,666,572 granted on 2023-06-06Treatment of HER2 positive cancers
#59 | 2022-05-05 ā Patent 12,071,480 granted on 2024-08-27CD47 antibodies and uses thereof for treating cancer
#60 | 2022-02-24Glycan-Interacting Compounds and Methods of Use
#61 | 2022-01-27 ā Patent 11,767,365 granted on 2023-09-26BCMA antibodies and use of same to treat cancer and immunological disorders
#62 | 2021-11-25 ā Patent 11,819,553 granted on 2023-11-21Glypican 3 antibodies and conjugates thereof
#63 | 2021-11-04ANTIBODIES TO INTEGRIN AVB6 AND USE OF SAME TO TREAT CANCER
#64 | 2021-10-14 ā Patent 11,369,658 granted on 2022-06-28Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
#65 | 2021-09-16 ā Patent 11,559,582 granted on 2023-01-24Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
#66 | 2021-09-16 ā Patent 11,510,959 granted on 2022-11-29Hydrophilic antibody-drug conjugates
#67 | 2021-09-02Anti-TIGIT Antibodies
#68 | 2021-07-22 ā Patent 11,820,827 granted on 2023-11-21Methods of treating myelodysplastic syndrome and acute myeloid leukemia with nonfucosylated anti-CD70 antibodies
#69 | 2021-07-01 ā Patent 11,827,709 granted on 2023-11-28Anti-AVB6 antibodies and antibody-drug conjugates
#70 | 2021-05-13 ā Patent 11,077,164 granted on 2021-08-03Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
#71 | 2021-05-06CD123 Antibodies and Conjugates Thereof
#72 | 2021-04-08 ā Patent 12,421,312 granted on 2025-09-23ANTI-PD-L1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
#73 | 2021-04-01 ā Patent 11,634,503 granted on 2023-04-25Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
#74 | 2021-01-14 ā Patent 11,857,565 granted on 2024-01-02Hydrophobic Auristatin F compounds and conjugates thereof
#75 | 2020-11-19 ā Patent 11,612,666 granted on 2023-03-28Process for the preparation of drug linker compounds
#76 | 2020-10-01 ā Patent 10,940,178 granted on 2021-03-09Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
#77 | 2020-09-24 ā Patent 11,389,543 granted on 2022-07-19Process for the preparation of tubulysins and intermediates thereof
#78 | 2020-08-06 ā Patent 11,617,798 granted on 2023-04-04Anti-CD228 antibodies and antibody-drug conjugates
#79 | 2020-07-16 ā Patent 11,730,822 granted on 2023-08-22Process for the preparation of glucuronide drug-linkers and intermediates thereof
#80 | 2020-06-25 ā Patent 11,931,414 granted on 2024-03-19Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
#81 | 2020-06-18 ā Patent 11,207,324 granted on 2021-12-28Treatment of HER2 positive cancers
#82 | 2020-05-14 ā Patent 11,891,644 granted on 2024-02-06T cells with reduced surface fucosylation and methods of making and using the same
#83 | 2020-04-30 ā Patent 11,541,128 granted on 2023-01-03Multi-drug antibody drug conjugates
#84 | 2020-04-16 ā Patent 11,667,696 granted on 2023-06-06Selective reduction of proteins
#85 | 2020-04-09 ā Patent 11,366,118 granted on 2022-06-21Detection and treatment of CD30 cancers
#86 | 2020-02-27 ā Patent 11,401,339 granted on 2022-08-02Anti-TIGIT antibodies
#87 | 2020-02-27 ā Patent 11,033,561 granted on 2021-06-15Methods of inhibition of protein fucosylation in vivo using fucose analogs
#88 | 2020-01-02 ā Patent 11,078,291 granted on 2021-08-03BCMA antibodies and use of same to treat cancer and immunological disorders
#89 | 2020-01-02 ā Patent 11,253,609 granted on 2022-02-22Glycan-interacting compounds and methods of use
#90 | 2019-12-26 ā Patent 11,844,839 granted on 2023-12-19Process for the preparation of pegylated drug-linkers and intermediates thereof
#91 | 2019-11-21 ā Patent 11,230,610 granted on 2022-01-25Bivalent antibodies masked by coiled coils
#92 | 2019-10-17 ā Patent 11,638,762 granted on 2023-05-02Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
#93 | 2019-09-12 ā Patent 11,319,526 granted on 2022-05-03Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
#94 | 2019-09-12 ā Patent 11,401,330 granted on 2022-08-02Glycan-interacting compounds and methods of use
#95 | 2019-08-29 ā Patent 11,191,771 granted on 2021-12-07Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
#96 | 2019-06-20 ā Patent 11,180,552 granted on 2021-11-23CD47 antibodies and uses thereof for treating cancer
#97 | 2019-06-20 ā Patent 11,607,460 granted on 2023-03-21Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
#98 | 2019-06-06 ā Patent 11,944,689 granted on 2024-04-02Drug conjugates with self-stabilizing linkers having improved physiochemical properties
#99 | 2019-05-09 ā Patent 11,110,179 granted on 2021-09-07Combination of CD33 antibody drug conjugates with chemotherapeutic agents
#100 | 2019-03-21 ā Patent 11,325,980 granted on 2022-05-10Combination therapy using a LIV1-ADC and a chemotherapeutic
Also check out Seagen Inc.'s (Bothell, United States) applicant profile with 117 patent applications submitted.
309062 ā